LGND250516P60000
- 3.21
- 0.000.00%
Ligand Pharmaceuticals Newsroom
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Ligand Pharmaceuticals Analyst Ratings
Stifel Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $143
Stifel Initiates Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $143
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $160
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $155
Benchmark Co. Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $135
Oppenheimer Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Cuts Target Price to $142
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $135 to $160
RBC Raises Price Target on Ligand Pharmaceuticals to $155 From $143, Keeps Outperform Rating
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $160
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Benchmark Co. Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $135
Ligand Pharmaceuticals Is Maintained at Overweight by Barclays
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $160
Ligand Pharmaceuticals Is Maintained at Outperform by RBC Capital
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Oppenheimer Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $151
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $143